Skip to main content

Table 1 Patient demographics, rFVIIa dose, mortality and thrombo-embolic complications

From: Use of activated recombinant factor VII for severe coagulopathy post ventricular assist device or orthotopic heart transplant

Pt Sex Age (yrs) 1st Dose (mg) 2nd Dose (mg) 3rd Dose (mg) Total rFVIIa (μg/kg) Procedure* Death Cause of Death TE episode Associated Risk Factors
1 M 51 7.2 4.8 - 143 VAD to OHT Y Graft Failure N N
2 M 53 2.4 - - 24 VAD to OHT N - N N
3 M 42 2.4 - - 36 VAD N - Y (ATΨ) N
4 M 52 4.8 4.8 - 77 VAD to OHT Y CVA** (embolic) Y Atherosclerosis
5 M 61 2.4 1.2 - 36 VAD N - N HIT^
6 M 64 4.8 - - 72 VAD to OHT N - N N
7 M 62 4.8 - - 56 VAD to OHT N - Y (DVT)¥ N
8 M 53 2.4 2.4 1.2 80 VAD Y CVA (air embolism) ? N
9 M 57 2.4 2.4 1.2 71 OHT N - N N
10 M 53 4.8 - - 48 VAD to OHT N - N N
11 F 38 1.2 1.2 - 32 VAD to OHT N - N N
12 F 51 2.4 6 6 189 VAD Y CVA (embolic) Y HIT^
13 F 67 4.8 2.4 - 109 VAD Y Heart Failure N Y (Multiorgan failure), ABIOMED#
14 F 46 4.8 4.8 1.2 150 VAD to OHT N - N N
15 M 49 4.8 - - 49 VAD to OHT N - N N
  1. *VAD = ventricular assist device, OHT = orthotopic heart transplant
  2. **CVA = cerebro-vascular accident
  3. TE = thrombo-embolic
  4. ΨAT = Right lower extremity arterial thrombus
  5. ¥DVT = Deep vein thrombosis
  6. ^HIT = Heparin induced thrombocytopenia, #ABIOMED = ABIOMED Left Ventricular Assist Device